Categorized | Civil Justice Update

BMS schedules settlement talks over novel hep C drug claims.

The Wall Street Journal (1/16, B3, Rockoff, Subscription Publication, 2.29M) reports that Wednesday marks the start of a series of talks that Bristol-Myers Squibb Co. has scheduled in an effort to settle personal-injury claims related to its hepatitis C drug candidate, 094. Although BMS has not provided details, the Journal says that persons with knowledge of the matter, as well as court documents, indicate that the New York City-based pharmaceutical firm is facing claims, amounting to more than $500 million, for the injuries and one death that occurred last year during company-sponsored clinical trials to test the treatment in patients with hepatitis C. 

Comments are closed.

Product Safety News

Top Practice Areas

Philadelphia
Mesothelioma, Medical Malpractice, Birth Injury, Spinal Cord Injury, Failure to Diagnose Cancer, Cerebral Palsy, Brain Injury, Personal Injury, Car Accidents, Truck Accidents

New Jersey
Birth Injury, Medical Malpractice, Mesothelioma, Personal Injury, Car Accidents, Truck Accidents

Cohen, Placitella & Roth, P.C.

Archives